(Q47344446)

14 January 2018

title

Long-term persisting interferon beta-1b neutralizing antibodies after discontinuation of treatment (English)

1 reference

14 January 2018

1 reference

Reske D

1

1 reference

14 January 2018

Walser A

series ordinal

2

1 reference

14 January 2018

Haupt WF

series ordinal

3

1 reference

14 January 2018

Petereit HF

series ordinal

4

1 reference

14 January 2018

language of work or name

English

0 references

publication date

1 January 2004

1 reference

14 January 2018

Acta Neurologica Scandinavica

published in

1 reference

14 January 2018

volume

109

1 reference

14 January 2018

issue

1

1 reference

14 January 2018

page(s)

66-70

1 reference

14 January 2018

PRISMS-4: Long-term efficacy of interferon-beta-1a in relapsing MS.

cites work

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0404.2003.00180.X

Neutralizing antibodies reduce MxA protein induction in interferon-beta-1a-treated MS patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0404.2003.00180.X

Production of high-titered interferon in cultures of human diploid cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0404.2003.00180.X

Memory B-cell persistence is independent of persisting immunizing antigen.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0404.2003.00180.X

Plasma cells for a lifetime?

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0404.2003.00180.X

Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0404.2003.00180.X

7 January 2021

Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0404.2003.00180.X

7 January 2021

Neutralizing antibodies during treatment of multiple sclerosis with interferon beta-1b: experience during the first three years. The IFNB Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0404.2003.00180.X

7 January 2021

Neutralizing antibodies and the efficacy of interferon beta-1b in relapsing-remitting multiple sclerosis

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0404.2003.00180.X

7 January 2021

Evidence of interferon beta-1a dose response in relapsing-remitting MS: the OWIMS Study. The Once Weekly Interferon for MS Study Group

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0404.2003.00180.X

7 January 2021

Guidelines for physicians with patients on IFN beta-1b: the use of an assay for neutralizing antibodies (NAB)

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0404.2003.00180.X

7 January 2021

A novel bioassay for the determination of neutralizing antibodies to IFN-beta1b.

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0404.2003.00180.X

7 January 2021

Systemic recombinant human interferon-beta treatment of relapsing-remitting multiple sclerosis: pilot study analysis and six-year follow-up

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0404.2003.00180.X

7 January 2021

The evolution of neutralizing antibodies in multiple sclerosis patients treated with interferon beta-1b

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0404.2003.00180.X

7 January 2021

High avidity IFN-neutralizing antibodies in pharmaceutically prepared human IgG.

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0404.2003.00180.X

7 January 2021

10.1034/J.1600-0404.2003.00180.X

Identifiers

DOI

1 reference

14 January 2018

PubMed ID

14653853

1 reference

14 January 2018